Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 68981105 | 6898110 | 5 | F | 20080822 | 20160913 | 20090202 | 20160921 | EXP | JP-BRISTOL-MYERS SQUIBB COMPANY-14488019 | BRISTOL MYERS SQUIBB | 32.15 | YR | M | Y | 82.40000 | KG | 20160921 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 68981105 | 6898110 | 1 | PS | ARIPIPRAZOLE. | ARIPIPRAZOLE | 1 | Oral | 10 MG, QD | 1316 | MG | 21436 | 10 | MG | ORAL POWDER | QD | ||||
| 68981105 | 6898110 | 2 | SS | ARIPIPRAZOLE. | ARIPIPRAZOLE | 1 | Oral | 15 MG, QD | 1316 | MG | 21436 | 15 | MG | ORAL POWDER | QD | ||||
| 68981105 | 6898110 | 3 | SS | ARIPIPRAZOLE. | ARIPIPRAZOLE | 1 | Oral | 18 MG, QD | 1316 | MG | 21436 | 18 | MG | ORAL POWDER | QD | ||||
| 68981105 | 6898110 | 4 | SS | ARIPIPRAZOLE. | ARIPIPRAZOLE | 1 | Oral | 30 MG, QD | 1316 | MG | 21436 | 30 | MG | ORAL POWDER | QD | ||||
| 68981105 | 6898110 | 5 | C | RISPERDAL | RISPERIDONE | 1 | Oral | 8 MG, QD | 1024 | MG | U | 0 | 8 | MG | QD | ||||
| 68981105 | 6898110 | 6 | C | RISPERDAL | RISPERIDONE | 1 | Oral | 12 MG, QD | 1024 | MG | U | 0 | 12 | MG | QD | ||||
| 68981105 | 6898110 | 7 | C | RISPERDAL | RISPERIDONE | 1 | Oral | 10 MG, QD | 1024 | MG | U | 0 | 10 | MG | QD | ||||
| 68981105 | 6898110 | 8 | C | RISPERDAL | RISPERIDONE | 1 | Oral | 8 MG, QD | 1024 | MG | U | 0 | 8 | MG | QD | ||||
| 68981105 | 6898110 | 9 | C | FLUNITRAZEPAM | FLUNITRAZEPAM | 1 | Oral | 1 MG, QD | 107 | MG | U | 0 | 1 | MG | TABLET | QD | |||
| 68981105 | 6898110 | 10 | C | FLUNITRAZEPAM | FLUNITRAZEPAM | 1 | Oral | 2 MG, QD | 107 | MG | U | 0 | 2 | MG | TABLET | QD | |||
| 68981105 | 6898110 | 11 | C | WYPAX | LORAZEPAM | 1 | Oral | 1.5 MG, QD | U | 0 | 1.5 | MG | TABLET | QD | |||||
| 68981105 | 6898110 | 12 | C | TASMOLIN | BIPERIDEN | 1 | Oral | 3 MG, QD | U | 0 | 3 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 68981105 | 6898110 | 1 | Schizophrenia |
| 68981105 | 6898110 | 5 | Schizophrenia |
| 68981105 | 6898110 | 9 | Schizophrenia |
| 68981105 | 6898110 | 11 | Schizophrenia |
| 68981105 | 6898110 | 12 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 68981105 | 6898110 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 68981105 | 6898110 | Insomnia | |
| 68981105 | 6898110 | Persecutory delusion | |
| 68981105 | 6898110 | Schizophrenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 68981105 | 6898110 | 1 | 20080719 | 0 | ||
| 68981105 | 6898110 | 2 | 20080802 | 20080823 | 0 | |
| 68981105 | 6898110 | 3 | 20080824 | 20081016 | 0 | |
| 68981105 | 6898110 | 4 | 20081017 | 0 | ||
| 68981105 | 6898110 | 5 | 20080604 | 20081016 | 0 | |
| 68981105 | 6898110 | 6 | 20081017 | 20090107 | 0 | |
| 68981105 | 6898110 | 7 | 20090108 | 20090318 | 0 | |
| 68981105 | 6898110 | 8 | 20090319 | 0 | ||
| 68981105 | 6898110 | 9 | 20080604 | 20080918 | 0 | |
| 68981105 | 6898110 | 10 | 20080919 | 0 | ||
| 68981105 | 6898110 | 11 | 20080604 | 0 | ||
| 68981105 | 6898110 | 12 | 20080604 | 0 |